CG Oncology, Inc. (CGON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings ...

We recently published an article titled Why Traders Flocked to These 10 Stocks on Monday. In this article, we are going to ...

CG Oncology shares rose Monday after the company shared positive data from a study of its bladder-cancer treatment. The stock gained 39% to $31.10 in premarket trading.

Shares of CG Oncology catapulted Monday after the biotech unveiled promising results for a J&J-rivaling bladder cancer ...

Shares of CG Oncology Inc. gained 25% April 28 on the back of phase III data presented at the American Urological Association meeting over the weekend showing its cretostimogene grenadenorepvec ...

With an FDA review underway, Johnson & Johnson is aiming to “fundamentally change” how bladder cancer is treated. | With an ...

Bladder cancer is the sixth most common form of cancer ... been established by the FDA or any other health authority. About CG Oncology CG Oncology is a late-stage clinical biopharmaceutical ...

BOND-003 evaluated the efficacy and safety of cretostimogene grenadenorepvec, an oncolytic immunotherapy, in patients with carcinoma in situ BCG-unresponsive NMIBC.

CG Oncology, Inc. (NASDAQ: CGON) has recently announced promising results for cretostimogene grenadenorepvec monotherapy at the 2025 American Urological Association (AUA) Annual Meeting. The phase 3 ...

Henry Khederian CG Oncology Touts Encouraging Data From Late-Stage Study Of Bladder Cancer Candidate CG Oncology's BOND-003 trial reveals durable efficacy of cretostimogene in NMIBC patients ...

Johnson & Johnson has kicked off a marketing application in the US for TAR-200 as a treatment for a form of bladder cancer ... Another potential rival - CG Oncology's retostimogene grenadenorepvec ...